Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1611039

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1611039

Anti-vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth & Trends:

The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 12.90 billion by 2030, registering a CAGR of -2.35% over the forecast period, according to a new report by Grand View Research, Inc. Increased funding for R&D of anti-VEGF therapeutics to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products coupled with the increasing geriatric population that is susceptible to develop ophthalmic diseases is expected to propel the market growth over the forecast period.

According to the United Nations Department of Economic and Social Affairs data, the global elderly population (aged 60 years and above) was around 703 million in 2019. The share of the population aged 65 years and above was 6%, which increased to 9% in 2019. The aging population, based on countries, was around 68.7 million in Africa, 549.2 million in Asia, 183 million in Europe, 78.4 million in North America, and more than 76 million in Latin America & other regions in 2017. Hence, the increasing geriatric population is anticipated to drive the market.

The lack of reimbursement policies in developing regions is creating an opportunity for cost-effective novel molecules. In addition, ophthalmologists switching to more effective newly launched drugs has compelled companies to invest in R&D to maintain their industry position. The interest of investigators on biosimilar of existing drugs is a major trend in the pipeline of anti-VEGF therapeutics.

Moreover, companies are developing various formulations and drug delivery systems that may increase the adoption of these therapies. For instance, F. Hoffmann La Roche Ltd. is developing the port delivery system-RG6321 (Ranibizumab)-which is currently undergoing a phase III clinical trial. It is an eye implant that is refillable and continuously delivers a customized formulation of ranibizumab over a period of months.

Loss of patent protection is likely to have a negative impact on the market growth and has led big pharma companies to consider new revenue streams. However, this is creating an emerging market for biosimilar drug producers in the space. This rising competition is anticipated to impede market growth. However, the launch of novel products with a competitive advantage is anticipated to lower the impact of the restraint during the forecast period.

Anti-vascular Endothelial Growth Factor Therapeutics Market Report Highlights:

  • In 2024, Age-related Macular Degeneration (AMD) accounted for the largest revenue share and is anticipated to maintain its dominance over the forecast period
  • Eylea dominated the product segment with the largest market share of 61.9% in 2024. Eylea (aflibercept), developed by Regeneron Pharmaceuticals in collaboration with Bayer, has been a foremost anti-VEGF therapy for treating retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO
  • North America anti-vascular endothelial growth factor therapeutics market dominated the global industry and accounted for 65.71% of revenue share in 2024, which can be attributed to the increasing prevalence of eye-related conditions such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and macular edema
Show more
Product Code: GVR-4-68038-346-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Disease outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Advancements in drug delivery and development
      • 3.2.1.3. Rising awareness about early diagnosis and treatment of ocular disorders
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of anti-VEGF therapeutics
      • 3.2.2.2. Potential side effects and safety concerns
  • 3.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Movement Analysis
  • 4.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Eylea
    • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.6. Lucentis
    • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.7. Beovu
    • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.8. Vabysmo
    • 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Movement Analysis
  • 5.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Macular Edema
    • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6. Diabetic Retinopathy
    • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7. Retinal Vein Occlusion
    • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.8. Age-related Macular Degeneration
    • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.9. Myopic Choroidal Neovascularization
    • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company overview
    • 7.4.1. Regeneron Pharmaceuticals, Inc.
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bayer AG
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. F. Hoffmann-La Roche Ltd.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Biogen
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Pfizer, Inc.
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Coherus BioSciences, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amgen, Inc.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Bausch Health Companies, Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Viatris, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
Show more
Product Code: GVR-4-68038-346-1

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 5 North America anti-vascular endothelial growth factor therapeutics, by region, 2018 - 2030 (USD Billion)
  • Table 6 North America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 7 North America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 8 U.S. anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 9 U.S. anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 10 Canada anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 12 Mexico anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 13 Mexico anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 14 Europe anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 15 Europe anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 16 Europe anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 17 UK anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 18 UK anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 19 Germany anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 20 Germany anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 21 France anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 22 France anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 23 Italy anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 24 Italy anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 25 Spain anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 26 Spain anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 27 Denmark anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 28 Denmark anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 29 Norway anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 30 Norway anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 31 Sweden anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 32 Sweden anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 36 Japan anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 37 Japan anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 38 China anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 39 China anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 40 India anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 41 India anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 42 Australia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 43 Australia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 44 South Korea anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 45 South Korea anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 46 Thailand anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 47 Thailand anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 48 Latin America anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 49 Latin America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 50 Latin America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 51 Brazil anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 52 Brazil anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 53 Argentina anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 54 Argentina anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 55 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 56 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 57 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 58 South Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 59 South Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 60 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 62 UAE anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 63 UAE anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Anti-vascular endothelial growth factor therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and disease segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Parent market value, 2024 (USD Billion)
  • Fig. 12 Market dynamics
  • Fig. 13 Prevalence of diabetic retinopathy in the U.S. in 2021
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Anti-vascular endothelial growth factor therapeutics market: Product outlook and key takeaways
  • Fig. 17 Anti-vascular endothelial growth factor therapeutics market: Product movement analysis
  • Fig. 18 Eylea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Lucentis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Beovu market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Vabysmo market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Anti-vascular endothelial growth factor therapeutics market: Disease outlook and key takeaways
  • Fig. 24 Anti-vascular endothelial growth factor therapeutics market: Disease movement analysis
  • Fig. 25 Macular edema market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Diabetic retinopathy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Retinal vein occlusion market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Age-related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Myopic choroidal neovascularization market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Anti-vascular endothelial growth factor therapeutics market revenue, by region, 2024 & 2030 USD Million
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 U.S. anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Prevalence of Diabetic Retinopathy (DR) in 2021, in U.S., in Million
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Mexico anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 UK anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Germany anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 France anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Spain anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Italy anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Denmark anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Sweden anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Norway anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Japan anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 China anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 India anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Australia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Thailand anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Korea anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Brazil anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Argentina anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamic
  • Fig. 87 Kuwait anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Rest of MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Company/competition categorization
  • Fig. 90 Company market share analysis, 2024
  • Fig. 91 Strategy mapping
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!